The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries

Journal of the American College of Surgeons

Volumn 196, Issue 5, 2003, Pages 691-697

  Schreiber, Martin A ^a,h   Holcomb, John B ^b   Hedner, Ulla ^c,d   Brundage, Susan I ^e   Macaitis, Joseph M ^b   Aoki, Nori ^f   Meng, Zhi Hong ^g   Tweardy, David J ^a   Hoots, Keith ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^c LUND UNIVERSITY   (Sweden)

^d NOVO NORDISK A S   (Denmark)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g DUKE UNIVERSITY   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; GLYCOPYRRONIUM BROMIDE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TELAZOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLEEDING; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HISTOLOGY; LAPAROTOMY; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; RESUSCITATION; SPLENECTOMY; SWINE; THROMBOSIS;

EID: 0038327506     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(02)01835-5     Document Type: Article

References (28)

1. Bonne RJ, Fulco CE, Liverman CT, eds. Reducing the burden of injury: advancing prevention and treatment. Committee on Injury Prevention and Control, Institute of Medicine. Washington, DC: National Academy Press, 1999.
2. Sauaia AS, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: A reassessment. J Trauma 1995;38:185-193.
3. Hedner U. Recombinant activated Factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998;9[Suppl 1]:S147-S152.
4. Hedner U. Treatment of patients with Factor VIII and Factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999;82:531-539.
5. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.
6. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant Factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 1997;113:1930-1936.
7. Papatheodoridis GV, Chung S, Keshav S, et al. Correction of both prothrombin time and primary haemostasis by recombinant Factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol 1999;31:747-750.
8. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant Factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26[Suppl 1]:159-164.
9. Tengborn L, Petruson B. A patient with Glanzmann's thrombasthenia and epistaxis successfully treated with recombinant Factor VIIa. Thromb Haemost 1996;75:981-982.
10. Douri MA, Shafi T, Khudairi DA, et al. Effect of the administration of recombinant activated Factor VII (rFVIIa; Novo-Seven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11[Suppl 1]:S121-S127.
11. White B, Ravi N, McHale J, et al. Successful use of recombinant FVIIA (Novoseven) in the management of intractable post surgical intra-abdominal haemorrhage. Br J Haematol 1999;107:677-678.
12. Vlot AJ, To E, Mackaay AJ, et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant Factor VII. Am J Med 2000;108:421-423.
13. Kalicinski P, Kaminski A, Drewniak T. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated Factor VII. Transplant Proc 1999;31:378-379.
14. Kenet G, Walden R, Eldad A, et al. Treatment of traumatic bleeding with recombinant Factor VIIa. Lancet 1999;354:1879.
15. Kamphuisen PW, Van de Akker JM, Kaasjager KA, et al. Control of life-threatening pulmonary bleeding with activated recombinant Factor VII. Am J Med 2002;112:332-333.
16. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated Factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-439.
17. Martinowitz U, Holcomb JB, Pusateri AE, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with Grade V liver injuries. J Trauma 2001;50:721-729.
18. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant Factor VIIa on coagulopathic pigs with Grade V liver injuries. J Trauma 2002;53:252-259.
19. Moore EE, Cogbill TH, Jurkovich GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995;38:323-324.
20. Holcomb JB, Pusateri AE, Harris RA, et al. Effect of dry fibrin sealant dressings versus gauze packing on blood loss in Grade V liver injuries in resuscitated swine. J Trauma 1999;46:49-57.
21. Kjalke M, Monroe DM, Hoffman M, et al. High-dose Factor VIIa restores platelet activation and total thrombin generation in a model system mimicking haemophilia A or B conditions. Thromb Hemost 1999;82(S1):303; abstract 951.
22. Rao VM, Rapaport SI. Factor VIIa-catalyzed activation of Factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused Factor VIIa. Blood 1990;75:1069-1073.
23. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose Factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547.
24. Monroe DM, Hoffman M, Oliver JA, et al. A possible mechanism of action of activated Factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998;9[Suppl 1]:S15-S20.
25. Hoffman M, Monroe DM, Roberts HR. Activated Factor VII activates Factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated Factor VII. Blood Coagul Fibrinolysis 1998;9[Suppl 1]:S61-S65.
26. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant Factor VIIa in plasma from patients with severe hemophilia A. Blood 2002;99:175-179.
27. Blombäck B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994;22:369-376.
28. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 202;42:114-124.